Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
about
The Role of Genomic Profiling in Advanced Breast Cancer: The Two Faces of JanusThe minority report: targeting the rare oncogenes in NSCLCMechanisms and therapeutic advances in the management of endocrine-resistant breast cancerCIViC databasePrognostic value of FGFR gene amplification in patients with different types of cancer: a systematic review and meta-analysis.Fibroblast Growth Factor Receptor Family Members as Prognostic Biomarkers in Head and Neck Squamous Cell Carcinoma: A Systematic Review.Escaping Antiangiogenic Therapy: Strategies Employed by Cancer CellsRecent developments and translational aspects in targeted therapy for metastatic breast cancerInhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical applicationTailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015Data integration to prioritize drugs using genomics and curated data.Novel Strategies to Improve the Endocrine Therapy of Breast Cancer.Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers.Pediatric low-grade gliomas: how modern biology reshapes the clinical field.A novel decoy receptor fusion protein for FGF-2 potently inhibits tumour growth.Prognostic value of miR-375 and miR-214-3p in early stage oral squamous cell carcinoma.Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?Fibroblast growth factor receptors in breast cancer.DFG-out mode of inhibition by an irreversible type-1 inhibitor capable of overcoming gate-keeper mutations in FGF receptors.Impact of centralization on aCGH-based genomic profiles for precision medicine in oncology.Rationale for targeting fibroblast growth factor receptor signaling in breast cancerHighlights from the 14(th) St Gallen International Breast Cancer Conference 2015 in Vienna: Dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer.Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.Targeted therapies for ER+/HER2- metastatic breast cancer.The Effect of Mutations on Drug Sensitivity and Kinase Activity of Fibroblast Growth Factor Receptors: A Combined Experimental and Theoretical Study.Fibroblast surface-associated FGF-2 promotes contact-dependent colorectal cancer cell migration and invasion through FGFR-SRC signaling and integrin αvβ5-mediated adhesionTargeting multiple tyrosine kinase receptors with Dovitinib blocks invasion and the interaction between tumor cells and cancer-associated fibroblasts in breast cancer.The clinical pathological characteristics and prognosis of FGFR1 gene amplification in non-small-cell lung cancer: a meta-analysis.Consistent PLAG1 and HMGA2 abnormalities distinguish carcinoma ex-pleomorphic adenoma from its de novo counterpartsFibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive/human epidermal growth factor receptor-2-negative primary breast cancer.Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically low-risk patient as defined by targeted sequencing.rCGH: a comprehensive array-based genomic profile platform for precision medicine.Emerging therapeutic targets in metastatic progression: A focus on breast cancer.Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology.A Receptor Tyrosine Kinase Inhibitor, Dovitinib (TKI-258), Enhances BMP-2-Induced Osteoblast Differentiation In Vitro.FGFR Family Members Protein Expression as Prognostic Markers in Oral Cavity and Oropharyngeal Squamous Cell CarcinomaIntegrated tumor and germline whole-exome sequencing identifies mutations in MAPK and PI3K pathway genes in an adolescent with rosette-forming glioneuronal tumor of the fourth ventricle.A reciprocal regulatory circuit between CD44 and FGFR2 via c-myc controls gastric cancer cell growth.FGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage non-small cell lung cancer.Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.
P2860
Q26740184-44BE18B0-A207-43A9-8527-208B67CE851BQ26851636-61850925-5BA3-4BB3-B8B4-BC09DE69AF2DQ27001260-EB08239A-7F74-45A2-B937-92AF5CAA8A16Q27612411-1CB057C7-970D-4819-BBA9-17945C000640Q27853061-E3821C72-3ED1-45D9-BB51-A4F3BE91C80BQ27853178-C02BFAB8-FE78-4977-A98C-CFD0A79629F6Q28067753-52D6F738-5AA1-4DFE-AC99-4982198C4C43Q28072755-3A1740AE-8052-4458-ACD0-B4C0DF67FA22Q28079309-9D9800A3-9F59-486C-A35C-01F85BD8ADFFQ28085062-C734B485-F202-4FC4-BAA6-299F0861E943Q31102946-543053CF-435D-4D99-94FA-54357717AFEAQ33727284-2CBBB6BE-CEB0-44C6-B99B-45760DC66315Q33779701-8DCCA06E-423D-440B-8415-5C51EEC9E3AFQ33847771-EE875A31-871A-41BC-84C0-04BD5F83F6F7Q33877489-F5EA8A40-B2FE-47F5-B77E-B3AABAB0E092Q34420611-45D98CC9-B9C7-4895-AEBD-F9DD565BCA63Q34476337-A4F1FE3B-926B-43F2-BEF5-385DE77E6CDEQ34556066-0C5472E2-FBA3-403F-96D7-06E06FF5FB25Q34992813-029F383F-6B6D-420F-95E1-398D279C07D3Q35128506-7683DCC5-C781-44B5-82C3-7A458EC67932Q35131258-1A1A5EC5-7BD7-49CD-8052-6E4F8B2174EDQ35496344-EC7DF01E-3C25-48FF-891E-5DE457BA85D3Q35586700-7F87FACC-CB7B-4CDB-BE38-03AAF79AB6B4Q35658860-484F9B5A-97F8-4F12-AC63-64AA75F0AB23Q35752926-EB4CB036-5E85-454E-8214-B430297C2115Q35987339-7A8ED473-A30F-4AAF-A50D-DBC4D2EC8664Q36186386-3562E8E9-560F-4ED3-AE52-C7443BA8EB83Q36450685-BA9E95EE-A316-40AE-912C-4AE4E6B57383Q36623116-6B955973-97F3-4688-AE56-A800AA90B9DEQ36801189-66805F7A-8E9F-4E31-8599-1BC193323BBDQ36834857-40012759-FD91-478A-A101-B117093AB04DQ36845431-CF9DCD51-E203-4132-9A60-EE13A3283DC7Q36854062-F35B2B3F-6803-4040-8CFF-140EFA719103Q36900873-CD0488FC-85F6-4AD4-9611-14D81406947BQ36909540-F8AFC8C1-3E4A-4497-A80A-1D0C7CEF13BFQ37067161-C8B3E1DA-49EE-4BBB-A4CC-2F445E2C3029Q37212868-902DED66-7A54-4938-A9BD-08476A1C0C00Q37317641-96DC6CB8-C8BD-45B7-B75F-B84EFD722703Q37346563-C5B12B31-6A0D-417C-9157-6FF902CF9B70Q37350792-63993ED8-B356-4DE5-A0CA-D051CFC5FEFE
P2860
Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
@ast
Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
@en
Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
@nl
type
label
Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
@ast
Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
@en
Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
@nl
prefLabel
Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
@ast
Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
@en
Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
@nl
P2093
P3181
P1476
Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
@en
P2093
Alejandro Yovine
Andrea Kay
Diana Graus Porta
Florence Dalenc
John W Smith
Jose M Perez-Garcia
José Baselga
Mario Campone
Michael Shi
P304
P3181
P356
10.1158/1078-0432.CCR-13-0190
P407
P577
2013-07-01T00:00:00Z